TAVR: Reasons to Consider Mitral Annular Calcification

Courtesy of Dr. Carlos Fava.

TAVR: Reasons to Consider Mitral Annular CalcificationAortic valve calcification and mitral annular calcification have the same etiology and are frequently present in high-risk patients undergoing transcatheter aortic valve replacement (TAVR). The implications of mitral annular calcification for patients undergoing TAVR has not been entirely clarified yet.

 

The study examined 782 patients with severe aortic stenosis who underwent TAVR. Among these patients, 375 (49.9%) presented mitral annular calcification in the computerized tomography scan:

  • Mild: 30.4%
  • Moderate: 9.5%
  • Severe: 9.5%

 

Patients who experienced the highest rate of mitral annular calcification were the eldest (83 vs. 81.9 years old), those with chronic renal insufficiency, and those with a higher Society of Thoracic Surgeons (STS) score (8.8 vs. 7.5; p <0,001).

 

Procedural success was similar for all patients, and no differences in mortality and major complications were observed at 30 daysAt 1 year, severe mitral annular calcification was found to be an independent predictor of all-cause mortality (hazard ratio [HR]: 1.95; 95% confidence interval [CI]: 1.24-3.07; p = 0.004) and cardiovascular mortality (HR: 2.35; 95% CI: 1.19-4.66; p = 0.01). Furthermore, it was an independent predictor of the need for a new permanent pacemaker after TAVR (odds ratio [OR]: 2.83; 95% CI: 1.08-7.47; p = 0.03).

 

Conclusion

Half of the patients with severe aortic stenosis experience mitral annular calcification. Severe mitral annular calcification is associated with increased all-cause and cardiovascular mortality, and with conduction disorders after TAVR. This pathology should be included in future risk stratification models.

 

Courtesy of Dr. Carlos Fava. Buenos Aires Favaloro Foundation, Argentina.

 

Original title: Concomitant Mitral Annular Calcification and Severe Aortic Stenosis: Prevalence, Characteristics and Outcome Following Transcatheter Aortic Valve Replacement.

Reference: Yigal Abramowitz, et al. European Heart Journal Advance Access published December 30, 2016.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...